tiprankstipranks
MEI Pharma Explores Strategic Shifts, Leadership Changes
Company Announcements

MEI Pharma Explores Strategic Shifts, Leadership Changes

Pick the best stocks and maximize your portfolio:

MEI Pharma (MEIP) has shared an announcement.

MEI Pharma, Inc. is exploring strategic alternatives to enhance shareholder value, including potential transactions or an orderly company wind-down. Amid these changes, President and CEO David M. Urso, along with Chief Medical Officer Richard G. Ghalie, M.D., will depart but will receive severance and benefits, including COBRA coverage and accelerated stock option vesting. Both executives will also serve as consultants, aiding in asset liquidation, with hourly compensation and potential success fees tied to asset sales. Justin J. File has been appointed Acting CEO with an updated compensation package, including an increased base salary and bonus opportunity, plus a success fee based on future cash balances.

See more insights into MEIP stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMEI Pharma Reports Strategic Shift Amid Financial Losses
TheFlyMEI Pharma reports Q1 EPS ($1.20) vs. $8.46 last year
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App